132198-53-9Relevant articles and documents
4-Hydroxy-2-quinolones. 36. Synthesis of 2-R-oxazolo[4,5-c]quinolin-4(5H)-ones
Ukrainets,Taran,Sidorenko,Gorokhova,Turov
, p. 1328 - 1333 (1997)
We consider different variants for synthesis of 2-R-oxazolo[4,5-c]quinolin-4(5H)-ones based on 3-amino-1H-2-oxo-4-hydroxyquinolines and their 3-N-acyl derivatives. We show that in the latter case, formation of the oxazole ring is possible via two routes,
Rational Design, Synthesis and Evaluation of Oxazolo[4,5-c]-quinolinone Analogs as Novel Interleukin-33 Inhibitors
Byun, Youngjoo,Cho, Haelim,Ho Jeon, Young,Hoon Kim, Kyong,Jang, Geonhee,Kim, Yujin,Lee, Kiho,Lee, Taeyun,Ma, Chao,Paek, Jiwon,Park, Seonghu,Shin -, Yujin,Son, Sang-Hyun,Son, Seyoung,Woo Jung, Yong,Yong Lee, Ki
, p. 3702 - 3712 (2021/11/19)
Interleukin-33 (IL-33) is an epithelial-derived cytokine that plays an important role in immune-mediated diseases such as asthma, atopic dermatitis, and rheumatoid arthritis. Although IL-33 is considered a potential target for the treatment of allergy-rel
NOVEL QUINOLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASES SUCH AS ASTHMA OR ATOPIC DERMATITIS INCLUDING THE QUINOLINONE DERIVATIVE AS ACTIVE INGREDIENT
-
Paragraph 0028; 0063-0065, (2020/05/29)
The present invention relates to anovel quinolinone derivative compound that regulates intracellular signal transduction mediated by TSLP and IL-33 to exhibit efficacy in preventing or treating allergic diseases such as asthma or atopic dermatitis. The qu
Synthesis of 2-aryl-oxazolo[4,5-c]quinoline-4(5H)-ones and 2-aryl-thiazolo[4,5-c]quinoline-4(5H)-ones
Hodgetts, Kevin J.,Kershaw, Mark T.
, p. 2911 - 2914 (2007/10/03)
(Matrix presented) Novel and highly efficient syntheses of oxazolo[4,5-c]quinoline-4(5H)-ones (1) and thiazolo[4,5-c]quinoline-4(5H)-ones (2) from ethyl 2-chlorooxazole-4-carboxylate (4) and ethyl 2-bromo-5-chlorothiazole-4-carboxylate (13), respectively,
Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
-
, (2008/06/13)
This invention encompasses compounds of the formula: STR1 and the pharmaceutically acceptable non-toxic salts thereof wherein R 1, R 2, R 3, R 4, and W are variablesThese compounds are highly selective agonists, antagonists or inverse agonists for GABA a